Saturday 17 October 2026 Export PBLA’s income statement to Excel — free account

Panbela Therapeutics Inc.

0.00 0.00 NaN

Follow PBLA

Alert me

Market cap: $3.4M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.10%

Capital & Financial Ratios $m

Market Cap 3.35

Revenue —

Net Income (27.91)

Free Cash Flow (14.40)

Net Debt 4.05

Current Ratio 0.26

Debt/Equity (0.23)

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 99.50%

Next Y EPS Growth 83.13%

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2021	2022	2023	Q'24
Cash	12	1	3	0
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	—	—	5
	12	2	3	5

	2021	2022	2023	Q'24
Payables	1	3	10	11
ST’ Debt	—	1	1	1
Other	—	—	—	—
	3	8	12	20

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	(1)	(2)	—	—
’23	(10)	(6)	(7)	(3)	(25)
’22	(4)	(4)	(2)	(5)	(15)
’21	(2)	(2)	(1)	(2)	(7)
’20	(1)	(1)	(1)	(1)	(4)
’19	—	—	—	(3)	(3)
’18	—	—	—	—	(2)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(9)	0	(2)	—	—
’23	(10)	(6)	(6)	(3)	(25)
’22	(4)	(5)	(2)	(5)	(16)
’21	(2)	(2)	(1)	(2)	(7)
’20	(1)	(1)	(1)	(1)	(4)
’19	—	—	—	(3)	(3)
’18	—	—	—	—	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.28)	(1.47)	(1.48)	—	—
’23	(390.39)	(159.00)	(53.80)	(65.90)	(231.77)
’22	(6.49k)	(36.28k)	(5.05k)	(3.41k)	(40.79k)
’21	(5.53k)	(5.29k)	(3.84k)	(6.25k)	(20.90k)
’20	(6.51k)	(1.50k)	(5.05k)	(2.16k)	(14.89k)
’19	—	—	—	(0.15)	(26.13k)
’18	—	—	—	—	(1.52k)

Fiscal quarters ending in the months shown.

Group	Line	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e
Price, $
Price, $	Low	—	—	170,398.64	23,999.98	77,999.94	47,999.96	56,882.36	38,399.97	1,250.40	9.00	Analyst estimates 2024–2026 Powerpack
	High	—	—	1,703,986.38	1,079,991.38	359,999.72	167,999.86	239,999.81	211,199.83	57,599.95	4,509.60
People
People	Employees	—	—	—	—	—	5	6	6	7	8
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	—	—	—	—
	EBT	—	—	(5)	(11)	(6)	(7)	(5)	(11)	(35)	(25)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	—	(5)	0	(6)	(6)	(5)	(10)	(35)	(25)
	Depreciation	—	—	—	—	—	2	—	—	—	—
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	(1.60)	(2.91)	(1,519.92)	(26,131.39)	(14,894.89)	(20,900.90)	(40,786.79)	(231.77)
	Cash flow	—	—	(0.77)	(38.14)	(612.05)	(13,695.00)	(12,846.67)	(14,490.00)	(19,095.00)	(231.64)
	Capex	—	—	0.00	0.00	0.00	0.00	0.00	0.00	(825.00)	3.67
	Free cash flow	—	—	(0.77)	(38.14)	(612.05)	(13,695.00)	(12,846.67)	(14,490.00)	(19,920.00)	(227.97)
	Book value	—	—	(1.49)	(41.36)	68.72	6,925.00	28,160.00	20,424.00	(10,061.25)	(43.21)
	Shares, m	—	—	3	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(2)	(3)	(2)	(3)	(4)	(7)	(15)	(25)
	Capex	—	—	—	—	—	—	—	—	(1)	0
	Free cash flow	—	—	(2)	(3)	(2)	(3)	(4)	(7)	(16)	(25)
Balance, $m
Balance, $m	Working capital	—	—	(5)	(3)	0	1	8	10	(6)	(9)
	Total debt	—	—	3	2	0	0	—	—	6	5
	Net debt	—	—	3	2	(1)	(2)	(9)	(12)	5	3
	Shareholders’ equity	—	—	(5)	(4)	0	1	8	10	(8)	(5)
Returns, %
Returns, %	ROA	—	—	(621.90)	(2,365.79)	(425.59)	(245.93)	(73.60)	(89.35)	(391.41)	(301.11)
	ROIC	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	122.72	249.05	345.22	(750.15)	(96.98)	(108.63)	(3,230.05)	396.00

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CVKD Cadrenal Therapeutics, Inc.	$3.5M	— (loss-making)	—	—	n/m	+26.24% (above 0%: growing)	0.00%	0.00%	Compare
IOBTQ IO Biotech, Inc.	$3.5M	— (loss-making)	—	—	n/m	+11.22% (above 0%: growing)	0.00%	0.00%	Compare
UNBX UNITY Biotechnology, Inc.	$3.4M	— (loss-making)	— (loss-making)	—	n/m	−23.10% (below 0%: shrinking)	0.00%	0.00%	Compare
LIPO Lipella Pharmaceuticals Inc.	$3.4M	— (loss-making)	— (loss-making)	−36.44% (below 0%: shrinking)	n/m	−41.79% (below 0%: shrinking)	100.00%	0.00%	Compare
PBLA Panbela Therapeutics Inc.	$3.4M	— (loss-making)	—	—	n/m	+66.23% (above 0%: growing)	—	0.00%
CMND Clearmind Medicine Inc.	$3.3M	— (loss-making)	—	—	n/m	−77.94% (below 0%: shrinking)	0.00%	0.00%	Compare
ADXN Addex Therapeutics Ltd. Sponsored ADR	$3.2M	— (loss-making)	— (loss-making)	−100.78% (below 0%: shrinking)	n/m	−2.73% (below 0%: shrinking)	100.00%	0.00%	Compare
CLDI Calidi Biotherapeutics, Inc.	$3.2M	— (loss-making)	—	—	n/m	+11.16% (above 0%: growing)	—	0.00%	Compare
EOCN Eocene Ltd.	$3.2M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−67.74% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$3.3M	—	—	−100.00%	—	−12.92%	0.00%	0.00%

All 614 Biotechnology stocks →